KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $473.8 million.

  • Vir Biotechnology's Non-Current Assets rose 500.22% to $473.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 899.15%. This contributed to the annual value of $356.4 million for FY2024, which is 771.41% up from last year.
  • Per Vir Biotechnology's latest filing, its Non-Current Assets stood at $473.8 million for Q3 2025, which was up 500.22% from $456.8 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Non-Current Assets high stood at $580.9 million for Q1 2024, and its period low was $142.5 million during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $330.7 million (2022), whereas its average is $339.9 million.
  • In the last 5 years, Vir Biotechnology's Non-Current Assets surged by 16738.91% in 2021 and then plummeted by 3535.24% in 2025.
  • Quarter analysis of 5 years shows Vir Biotechnology's Non-Current Assets stood at $391.4 million in 2021, then dropped by 27.7% to $283.0 million in 2022, then grew by 16.9% to $330.8 million in 2023, then rose by 7.71% to $356.4 million in 2024, then soared by 32.95% to $473.8 million in 2025.
  • Its Non-Current Assets was $473.8 million in Q3 2025, compared to $456.8 million in Q2 2025 and $375.5 million in Q1 2025.